3D 바이오프린팅 시장 보고서 : 구성요소별, 용도별, 최종사용자별, 지역별(2026-2034년)
3D Bioprinting Market Report by Component (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2026-2034
상품코드:1941355
리서치사:IMARC
발행일:2026년 02월
페이지 정보:영문 142 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 3D 바이오프린팅 시장 규모는 2025년에 15억 7,530만 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 50억 4,000만 달러에 달하고, 2026년부터 2034년까지 CAGR 13.38%로 성장할 것으로 예측하고 있습니다. 고령 인구의 증가, 연구개발 활동에 대한 관심 증가, 시장 혼란이 적다는 점 등이 시장 성장을 이끄는 주요 요인으로 꼽힙니다.
3D 바이오프린팅 시장 동향:
의약품 시험 및 개발 증가
3D 바이오프린터는 약물 시험 및 임상시험의 적용에 있어 매우 중요합니다. 동물실험의 필요성을 크게 줄일 수 있을 것으로 기대되며, 윤리적인 측면에서도 유익하고 비용 효율적일 것으로 예상됩니다. 3D 바이오프린팅의 등장으로 의약품 개발자들은 인간과 유사한 3D 프린팅 조직에서 신약을 시험함으로써 인간 임상시험에 따른 합병증을 쉽게 파악할 수 있고, 후기 단계의 실패로 인한 손실을 줄일 수 있게 되었습니다. 또한, 기업의 R&D 투자 증가로 인해 3D 바이오프린팅과 같은 혁신 기술에 대한 수요가 더욱 증가하고 있습니다. 예를 들어, 미국 의회예산국(CBO)이 발표한 자료에 따르면, 2021년 현재 제약 업계는 2020년 전 세계적으로 약 2,000억 달러를 연구개발에 투자한 것으로 확인되었습니다. 이는 2019년 8,300만 달러에 비해 크게 증가한 수치입니다. 마찬가지로, 다나하 코퍼레이션은 2021년 연구개발에 17억 4,200만 달러를 투자할 계획이며, 이는 2020년 13억 4,800만 달러에서 증가한 금액입니다. 또한, 바이오 래드 연구소는 2021년에 8억 7,960만 달러를 투자했지만, 2020년에는 8억 3,000만 달러를 투자했습니다. 이러한 의약품 시험 및 의약품 개발에 대한 막대한 투자는 향후 몇 년 동안 3D 바이오프린팅 시장 규모를 확대할 것으로 예상됩니다.
기술적 진보
3D 바이오프린팅의 지속적인 기술 발전은 시장 전체에 더 많은 수익성 있는 성장 기회를 제공하고 있습니다. 또한, 주요 시장 기업들은 보다 진보되고 효율적인 3D 바이오프린팅 기술을 개발하기 위해 협력과 제휴를 추진하고 있습니다. 예를 들어, 2024년 6월에는 첨단 조직 모방 기술 기업인 로나우크가 B9Creations와 제휴하여 로나우크의 바이오 블록을 활용한 3D 바이오프린트 하이드로겔 개발 및 양산을 시작했습니다. 기존 방식은 세포를 인공적인 환경에 강제로 배치하는 반면, 로나우크의 바이오블록은 세포가 자연스럽게 조직을 형성할 수 있는 환경을 재현합니다. 이를 통해 인간이나 동물 조직의 본래 구조와 기능에 매우 근접한 조직을 얻을 수 있습니다. 마찬가지로, 2022년 9월 인도과학연구소(IISc)는 스웨덴에 본사를 둔 바이오프린팅 솔루션 기업 셀링크(CELLINK)와의 협업을 발표했습니다. 이를 통해 우수연구센터(CoE)에 2-3대의 바이오프린터가 제공되며, 각 프린터는 각기 다른 인쇄 기술을 채택하고 비용은 각 사가 부담합니다. 또한 2022년 12월에는 셀링크와 IISc가 공동으로 인도 최초의 3D 바이오프린팅 센터 오브 엑설런스를 방갈로르에 설립했습니다. 이러한 3D 바이오프린팅 분야의 혁신, 협력, 확대는 예측 기간 동안 3D 바이오프린팅 시장 전망에 긍정적인 영향을 미칠 것으로 예상됩니다.
암 연구에서의 제품 적용 확대
3D 바이오프린팅은 실제 인간 종양의 복잡성과 미세 환경을 충실하게 재현한 사실적인 종양 모델 제작에 널리 활용되고 있습니다. 이러한 바이오프린트 모델을 통해 연구자들은 통제된 환경에서 암의 진행, 전이, 종양-간질 상호작용을 연구할 수 있습니다. 또한, 전 세계적으로 증가하는 암 환자 수는 시장 전체에 더 많은 성장 기회를 제공하고 있습니다. 예를 들어, 국제암연구소(IARC)의 추산에 따르면, 2020년에는 약 1,929만 건의 암이 확인되었습니다. 2030년까지 2,458만 건으로 증가할 것으로 예상됩니다. 또한, GLOBOCAN에 따르면 2020년 미국에서는 약 228만 1,658건의 신규 암이 진단되었고, 암으로 인한 사망자 수는 61만 2,390명에 달했습니다. 또한, 폐암과 유방암은 개인에게 가장 흔한 두 가지 암입니다. 캐나다암협회(CCS)의 발표에 따르면, 2020년 약 2만 9,800명의 캐나다인이 폐암 진단을 받았으며, 이는 신규 암 발생의 13%를 차지합니다. 또한, 2020년에는 약 21,200명의 캐나다인이 폐암으로 사망할 것으로 예상되며, 이는 2020년 전체 암 사망자의 25%를 차지할 것으로 예측됩니다. 이러한 암 환자 증가는 효과적인 치료법 발굴, 약제 내성 기전 규명, 암 치료의 맞춤화를 지원하는 3D 바이오프린팅 기술에 대한 수요를 증가시키고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 3D 바이오프린팅 시장
제6장 시장 내역 : 구성요소별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSM
영문 목차
영문목차
The global 3D bioprinting market size reached USD 1,575.3 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 5,040.0 Million by 2034, exhibiting a growth rate (CAGR) of 13.38% during 2026-2034. The growing geriatric population, increasing focus on research and development (R&D) activities, and less disrupted market represent some of the key factors driving the market growth.
3D Bioprinting Market Analysis:
Major Market Drivers: The increasing utilization of 3D bioprinting in personalized medicine is primarily driving the growth of the market. 3D bioprinting can create patient-specific tissues and organs, enabling personalized treatment plans and reducing the risk of transplant rejection.
Key Market Trends: The escalating utilization of bioprinting to manufacture complex biomedical devices and implants with precise geometries and biological functionalities is one of the significant trends driving the growth of the market. Furthermore, rapid advancements in 3D bioprinting technology, including improved biomaterials and printing techniques, are also contributing to the market expansion.
Competitive Landscape: Some of the leading players operating in the global market include 3D Systems Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH, Materialise, Organovo Holdings Inc., Poietis, RegenHU, and Stratasys Ltd., among others.
Geographical Landscape: According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting. Some of the factors driving the North American 3D bioprinting market include the growing prevalence of various chronic diseases, the wide presence of key players, and increasing private and government investment.
Challenges and Opportunities: The global 3D bioprinting market faces challenges such as high costs, technical complexities, and regulatory hurdles. However, it presents opportunities to advance personalized medicine, improve drug testing accuracy, and address organ transplant shortages through innovative tissue engineering solutions.
3D Bioprinting Market Trends:
Increasing Drug Testing and Development
3D bioprinters are highly important for drug testing and clinical trial applications. They are expected to drastically reduce the need for animal trials, thus being ethically beneficial and cost-effective. With the advent of 3D bioprinting, drug developers can easily identify complications associated with human clinical trials by testing new drugs on human-like 3D-printed tissues, thereby reducing losses from late-stage failures. Additionally, the increasing investment in research and development by the companies is further escalating the demand for innovative technologies like 3D bioprinting. For instance, according to the data published by the Congressional Budget Office, in 2021, it has been observed that pharmaceutical industries spent nearly US$ 200 Billion on research and development in 2020 globally compared to US$ 83 Million in 2019. Similarly, Danaher Corporation invested US$ 1,742 Million in its research and development in 2021, as compared to US$ 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc. invested US$ 879.6 Million in 2021 as compared to US$ 800.3 Million in 2020. Such significant investments in drug trials and drug development are anticipated to propel the 3D bioprinting market size in the coming years.
Technological Advancements
Ongoing technological advancements in 3D bioprinting are further offering lucrative growth opportunities to the overall market. Additionally, various leading market players are collaborating and forming partnerships to develop more advanced and efficient 3D bioprinting technologies. For instance, in June 2024, advanced tissue mimetic technologies company Ronawk partnered with B9Creations to develop and mass-produce 3D bioprinted hydrogels leveraging Ronawk's Bio-Blocks. Unlike traditional methods that force cells into artificial environments, Ronawk's Bio-Blocks recreate conditions that allow cells to form tissues naturally. This results in tissue that closely resembles the native architecture and function of human and animal tissues. Similarly, in September 2022, the Indian Institute of Science (IISc) announced its collaboration with CELLINK, a Sweden-based bioprinting solutions company, to provide two to three bioprinters to the Centre of Excellence (CoE), each of which uses a different printing technology at its own cost. Additionally, in December 2022, CELLINK and IISc jointly established Bengaluru's pioneering 3D Bioprinting Centre of Excellence in India. Such innovations, collaborations, and expansion in 3D bioprinting are projected to positively impact the 3D bioprinting market outlook over the forecasted period.
Growing Product Application in Cancer Research
3D bioprinting is widely used in the creation of realistic tumor models that closely mimic the complexity and microenvironment of actual human tumors. These bioprinted models enable researchers to study cancer progression, metastasis, and tumor-stroma interactions in a controlled setting. Moreover, the escalating cases of cancer across the globe are further offering lucrative growth opportunities to the overall market. For instance, the International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Additionally, according to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. Such a substantial growth in cancer cases is augmenting the demand for 3D bioprinting technologies that help identify effective treatments, understand drug resistance mechanisms, and personalize cancer therapies.
Global 3D Bioprinting Industry Segmentation:
Component Insights:
3D Bioprinters
Syringe/Extrusion Bioprinting
Inkjet Bioprinting
Magnetic Levitation Bioprinting
Laser-assisted Bioprinting
Others
Scaffolds
Biomaterials
Living Cells
Hydrogels
Extracellular Matrices
Others
3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment
The 3D bioprinting market research report has provided a detailed breakup and analysis of the 3D bioprinting market based on the component. This includes 3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others). According to the report, 3D bioprinters (syringe or extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment.
The bolstering demand for 3D bioprinters can be attributed to the increasing utilization of syringe or extrusion-based bioprinting technology in printing various biological compounds or devices. They are widely used in fabricating tissue scaffolds for regenerative medicine, developing organ models for transplant research, and creating realistic tissue models for drug testing and cancer research. Moreover, 3D bioprinters have the ability to produce complex, customized biological structures, improve the accuracy of drug testing, and reduce the need for animal testing. As a result, they are widely used in the fields of tissue engineering, personalized medicine, pharmaceutical development, and medical research.
Application Insights:
Research
Drug Research
Regenerative Medicine
3D Cell Culture
Clinical
Skin
Bone and Cartilage
Blood Vessels
Others
Research (drug research, regenerative medicine, and 3D cell culture) accounted for the largest market share
The growth of this segment can be attributed to the widespread utilization of 3D printing technology among researchers to study the effects of different diseases and their progression and possible treatments. Moreover, it reduces the need to use lab animals for medical tests and dangerous trials on humans. Additionally, the 3D bioprinting market forecast by IMARC indicates that the increasing drug development and drug trial activities are bolstering the application of 3D bioprinting in research. For instance, with the COVID-19 pandemic behind, the US Food and Drug Administration (FDA) approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best yearly FDA harvest after 2018 (59 approvals) in all the series. Such a significant growth in drug trials and approval is creating a positive outlook for the overall market.
End User Insights:
Hospitals
Research Organization and Academic Institutes
Biopharmaceuticals Companies
Biopharmaceuticals companies accounted for the largest market share
The 3D bioprinting market statistics by IMARC indicate that the increasing number of target therapies is primarily driving the growth of this segment. In addition to this, the rising collaborations and mergers and acquisition activities among biopharmaceutical companies to develop 3D bioprinting are positively influencing the market. For instance, in June 2022, REGEMAT 3D, a company at the forefront of personalized bio fabrication solutions, announced a partnership with Humabiologics, a company providing human-derived biomaterials for regenerative medicine, in response to the growing demand and to serve a broader life sciences customer base of the industry partners and academic institutions in the European bioprinting and drug testing market.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America (the United States and Canada) was the largest market for 3D bioprinting
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting.
Some of the factors driving the North American 3D bioprinting market included the growing prevalence of various chronic diseases, the presence of key players, and increasing private and government investments. Additionally, new product launches by the key market players in the region, along with the easy allocation of funds to conduct R&D activities, are further creating a positive outlook for the overall market. For instance, in 2022, scientists from Florida Atlantic University and the University of Virginia created a robotic model of the human spine to assist surgeons in anticipating the outcomes of interventions before surgery. Thus, the increasing demand for 3D bioprinting for healthcare physicians is expected to boost the market over the forecast period. Additionally, the rising investments by the regional government authorities in the healthcare sector are projected to propel the 3D bioprinting market share in the coming years.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global 3D bioprinting market. Some of the companies covered in the report include:
3D Systems Inc.
Aspect Biosystems Ltd.
Cellink
Cyfuse Biomedical K.K.
EnvisionTEC GmbH (Desktop Metal Inc.)
GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH
Materialise
Organovo Holdings Inc.
Poietis
RegenHU
Stratasys Ltd.
Key Questions Answered in This Report
1.What was the size of the global 3D bioprinting market in 2025?
2.What is the expected growth rate of the global 3D bioprinting market during 2026-2034?
3.What are the key factors driving the global 3D bioprinting market?
4.What has been the impact of COVID-19 on the global 3D bioprinting market?
5.What is the breakup of the global 3D bioprinting market based on the component?
6.What is the breakup of the global 3D bioprinting market based on the application?
7.What is the breakup of the global 3D bioprinting market based on the end user?
8.What are the key regions in the global 3D bioprinting market?
9.Who are the key players/companies in the global 3D bioprinting market?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global 3D Bioprinting Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Component
6.1 3D Bioprinters
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Syringe/Extrusion Bioprinting
6.1.2.2 Inkjet Bioprinting
6.1.2.3 Magnetic Levitation Bioprinting
6.1.2.4 Laser-assisted Bioprinting
6.1.2.5 Others
6.1.3 Market Forecast
6.2 Scaffolds
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Biomaterials
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Living Cells
6.3.2.2 Hydrogels
6.3.2.3 Extracellular Matrices
6.3.2.4 Others
6.3.3 Market Forecast
7 Market Breakup by Application
7.1 Research
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Drug Research
7.1.2.2 Regenerative Medicine
7.1.2.3 3D Cell Culture
7.1.3 Market Forecast
7.2 Clinical
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Skin
7.2.2.2 Bone and Cartilage
7.2.2.3 Blood Vessels
7.2.2.4 Others
7.2.3 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Research Organization and Academic Institutes
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Biopharmaceuticals Companies
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 3D Systems Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Aspect Biosystems Ltd.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Cellink
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.4 Cyfuse Biomedical K.K.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 EnvisionTEC GmbH (Desktop Metal Inc.)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 GeSiM - Gesellschaft fur Silizium-Mikrosysteme mbH
